WazaGaY-1 是一种氮杂-BODIPY 衍生物,可作为 NIR-I/NIR-II 荧光造影剂,主要通过网格蛋白包被凹坑内吞进入肿瘤细胞,并蓄积在肿瘤细胞的细胞质中(包括肿瘤球的核心区域),可用于胶质母细胞瘤、卵巢癌以及黑色素瘤的研究 (Ex/Em = 685/820 nm)。
WazaGaY-1
产品编号: MS-J16148 分子式: C38H36GaI2N5O2 分子量: 918.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

WazaGaY-1 是一种氮杂-BODIPY 衍生物,可作为 NIR-I/NIR-II 荧光造影剂,主要通过网格蛋白包被凹坑内吞进入肿瘤细胞,并蓄积在肿瘤细胞的细胞质中(包括肿瘤球的核心区域),可用于胶质母细胞瘤、卵巢癌以及黑色素瘤的研究 (Ex/Em = 685/820 nm)。

生物实验数据

生物活性 WazaGaY-1 is an aza-BODIPY derivative that serves as a NIR-I/NIR-II fluorescent imaging agent, enters tumor cells primarily via clathrin-coated pit-mediated endocytosis, and accumulates in the cytoplasm of tumor cells, including the core region of tumor spheroids, making it applicable for research on glioblastoma, ovarian cancer, and melanoma (Ex/Em = 685/820 nm).
体外研究
(In Vitro)

WazaGaY-1 (0-500 μM) 在无细胞培养基中产生浓度依赖性荧光,在富含脂蛋白的血浆中荧光强度最高,可在 NIR-I 和 NIR-II 窗口中实现检测。
WazaGaY-1 (10 μM) 可在散射性脂肪乳溶液中实现 NIR-I 窗口下最深 4 mm、NIR-II 窗口下最深 6 mm 的荧光成像。
WazaGaY-1 (0.1-100 μM;72 小时) 在浓度高达 50 μM 时对 HUVEC、U87MG 和 HEK293 细胞无毒性,仅 HEK293 细胞在 100 μM 时表现出细胞毒性;它在 100 μM 浓度下可减小 U87MG 球状体的大小,且无显著细胞毒性。
WazaGaY-1 (10 μM, 50 μg/mL;30 分钟-24 小时) 会随时间在 U87MG 和 HEK293 细胞的细胞质中积累,且在 U87MG 细胞中的积累量更高,还能穿透进入 U87MG 细胞球的核心区域。
WazaGaY-1 (10 μM, 10 μg/mL;0.5-4 小时) 主要通过网格蛋白包被小凹被 U87MG 细胞内化,同时存在少量次要的主动转运途径,且与溶酶体或线粒体的共定位程度极低。

Cell Cytotoxicity Assay

Cell Line: Human endothelial HUVEC, glioblastoma U87MG, renal HEK293 cells; U87MG spheroids
Concentration: 0.1 μM; 1 μM; 5 μM; 10 μM; 25 μM; 50 μM; 100 μM
Incubation Time: 72 h
Result: Maintained cell viability above 85% for all three cell lines at concentrations from 0.1 to 50 μM in 2D cultures.
Induced cytotoxicity in HEK293 cells at 100 μM in 2D cultures.
Maintained cell viability above 85% and necrotic cell percentage below 2.5% at all tested concentrations in U87MG spheroids.
Reduced U87MG spheroid size to 85% of control at 10 μM and 50% of control at 100 μM.
体内研究
(In Vivo)

指南 (以下是我们推荐的方案,本方案仅提供指南,应根据您的具体需要进行修改)。
1. 体内成像
a. 取 10 mM WazaGaY-1 (溶于 DMSO) 储备溶液,用无菌 PBS 稀释至 1 mM 工作液。
b. 通过 0.2 μm 过滤器对工作液进行灭菌。立即使用,或一次性等份使用,并在 -20 °C 下储存,避免冻融循环,避免暴露在阳光下。
c. 成像前 5-72 小时,静脉注射总质量为 25-100 μg 的 WazaGaY-1 (即 27-109 μL 工作液)。
注:应为每个动物模型进行 WazaGaY-1 动力学研究,以确定峰值信号时间。
WazaGaY-1 (25-100 μg;静脉注射;单次给药) 可实现皮下 U87MG 肿瘤的清晰体内和体外检测,静脉给药后 72 小时的肿瘤与肌肉比值最高可达 20,其中 100 μg 剂量的肿瘤蓄积量和组织对比度比值最高。
WazaGaY-1 (100 μg;静脉注射;单次给药) 可用于检测皮下 IGROV-1 肿瘤,在静脉注射 100 μg 后 72 小时,其在 NIR-I 窗口的肿瘤与肌肉比值最高可达 20,在 NIR-II 窗口的比值最高可达 11.7。
WazaGaY-1 (100 μg;静脉注射;单次给药) 可通过 NIR-I 荧光成像特异性检测腹腔内 IGROV-1 肿瘤,在静脉注射 100 μg 后 48 小时,其肿瘤与周围组织的比值约为 1.8,这支持了其在荧光引导手术中的应用潜力。
WazaGaY-1 (100 μg;静脉注射;单次给药) 可在静脉注射 100 μg 后 72 小时,于 NIR-I 窗口实现皮下 A375 肿瘤的检测,其肿瘤/肌肉比值最高可达 20,在 NIR-II 窗口该比值最高可达 11.7;且其在 A375 肿瘤中的蓄积量低于在 U87MG 和 IGROV-1 肿瘤中的蓄积量。

Animal Model: NMRI nude mice (female, 6 weeks old)
Dosage: 25 μg; 50 μg; 100 μg
Administration: i.v.; single dose
Result: Detected U87MG tumors via NIR-I fluorescence (800 nm) from 5 to 72 hours post-injection for all doses.
Increased in vivo tumor-to-surrounding tissue ratios between 5 and 24 hours, stabilizing until 72 hours with ratios slightly above 2 at 24 hours.
Achieved ex vivo tumor-to-skin ratios ranging from 3 to 7.6, tumor-to-muscle ratios ranging from 14.4 to 20, and tumor-to-fat ratios ranging from 13 to 28.7 at 72 hours.
Showed significantly higher tumor-to-fat ratios for the 100 μg dose compared to 25 μg (p=0.002) and 50 μg (p=0.014).
Demonstrated significantly higher tumor fluorescence accumulation in the 100 μg dose group compared to the 25 μg and 50 μg groups (p < 0.001).
Animal Model: NMRI nude mice (female, 6 weeks old)
Dosage: 100 μg
Administration: i.v.; single dose
Result: Detected tumors via NIR-I imaging from 5 to 72 hours post-injection, with in vivo tumor-to-surrounding tissue ratios between 2 and 2.5.
Achieved ex vivo tumor-to-muscle ratios of 7-20 and tumor-to-fat ratios of 15-28 in NIR-I window at 72 hours.
Detected tumors via NIR-II imaging with maximum signal at 5 hours and signal persisting to 72 hours; achieved in vivo tumor-to-surrounding tissue ratios of 2.5, and ex vivo tumor-to-muscle ratios of 5-11.7 and tumor-to-fat ratios of 7-13.2 in NIR-II window at 72 hours.
Showed significantly lower tumor fluorescence accumulation than in U87MG tumors (p < 0.001) in both optical windows.\nShowed significantly higher signal in intraperitoneal tumors compared to surrounding tissue (p=0.0036) via NIR-I fluorescence imaging, with a tumor-to-surrounding tissue ratio of ~1.8 at 48 hours.
Showed no statistically significant difference in signal between tumors and surrounding tissue (p=0.1955) via NIR-II fluorescence imaging, with a tumor-to-surrounding tissue ratio of ~1.6 at 48 hours.
Demonstrated significantly higher NIR-I ratio than NIR-II ratio (p=0.0247).
Enabled clear visualization of tumors via NIR-I fluorescence, while tumors were difficult to identify via visual inspection alone.
Animal Model: NMRI nude mice (female, 6 weeks old)
Dosage: 100 μg
Administration: i.v.; single dose
Result: Detected tumors via NIR-I imaging from 5 to 72 hours post-injection, with in vivo tumor-to-surrounding tissue ratios between 2 and 2.5.
Achieved ex vivo tumor-to-muscle ratios of 7-20 and tumor-to-fat ratios of 15-28 in NIR-I window at 72 hours.
Detected tumors via NIR-II imaging with maximum signal at 5 hours and signal persisting to 72 hours; achieved in vivo tumor-to-surrounding tissue ratios of 2, and ex vivo tumor-to-muscle ratios of 5-11.7 and tumor-to-fat ratios of 7-13.2 in NIR-II window at 72 hours.
Showed significantly lower tumor fluorescence accumulation than in U87MG and IGROV-1 tumors (p < 0.001) in both optical windows.

化学信息

分子量 918.26
分子式 C38H36GaI2N5O2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础